| Title |
Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons
|
|---|---|
| Published in |
Clinical & Experimental Metastasis, December 2016
|
| DOI | 10.1007/s10585-016-9831-9 |
| Pubmed ID | |
| Authors |
Tapas Das, Sharmila Banerjee |
| Abstract |
Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects. Although a plethora of such radiopharmaceuticals have been developed and evaluated in animal models, only a few are regularly used in clinics while some of these agents are at different stages of clinical evaluations. The present article describes only those bone-seeking radiopharmaceuticals, which have been reported to be clinically administered till date, along with their relative merits and drawbacks. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 19% |
| Student > Master | 5 | 14% |
| Researcher | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Student > Postgraduate | 2 | 5% |
| Other | 5 | 14% |
| Unknown | 12 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 5% |
| Psychology | 2 | 5% |
| Engineering | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 13 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2017.
All research outputs
#21,358,731
of 23,854,458 outputs
Outputs from Clinical & Experimental Metastasis
#662
of 778 outputs
Outputs of similar age
#339,004
of 400,383 outputs
Outputs of similar age from Clinical & Experimental Metastasis
#3
of 3 outputs
Altmetric has tracked 23,854,458 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 778 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,383 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.